Amlodipine camsylate comparable to amlodipine besylate in terms of efficacy and safety profiles

Published: 2004-06-28 07:00:00

Updated: 2004-06-28 07:00:00

Hanmi Pharm said on June 24 that its amlodipine camsylate is comparable to Pfizer's Norvasc (amlodipine besylate) in terms of efficacy and safety profiles, adding that the former protects amlodipine from heat and moisture better than besylate salt, based on the clinical results collected from sev...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK